Global Intestinal Pseudo Obstruction Treatment Market Report 2022-2027 Featuring Pfizer, Cipla, GlaxoSmithKline, Teva., Eli Lilly and Co, Novartis, J&J, Dr. Reddy's Lab, F. Hoffmann-La Roche, Lupin

News provided by

May 20, 2022, 08:00 ET

DUBLIN, May 20, 2022 /PRNewswire/ -- The "Global Intestinal Pseudo Obstruction Treatment Market, By Condition (Acute v/s Chronic), By Diagnosis (Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Others), By Treatment, By End User, By Region, Competitional Forecast & Opportunities, 2017-2027" report has been added to ResearchAndMarkets.com's offering.

Global intestinal pseudo obstruction treatment market is anticipated to grow at a formidable rate with growth attributed to the increasing instances of complexities related to pseudo obstruction, a rare condition where muscle impairment causes disruption in the gastro-intestinal muscle contraction when neurons are not able to function properly.

If untreated, the intestinal pseudo obstruction could cause abdominal swelling, pain, nausea, constipation, or diarrhea. In extreme conditions, people can lose their appetite or may find difficulty in nutrient absorption, which can lead to malnutrition. Rapidly increasing incidences of various stomach ailments, indigestion, and other diseases are expected to drive the growth of the global intestinal pseudo obstruction treatment market.

The risk of pseudo obstruction increases with aging due to neural degeneration or muscle abnormalities, thus increasing geriatric population across the globe is contributing to the growth of intestinal pseudo obstruction treatment market. Increasing advancements in technology and rising research initiatives towards products and treatment methodologies for intestinal pseudo obstruction treatment are some of the factors expected to propel the growth of pseudo obstruction treatment market in the next five years.

New innovations in gastro intestinal imaging and manometry of the organ tract are supporting the growth of the global intestinal pseudo obstruction treatment market.

Furthermore, rising healthcare expenditure and growing initiatives by public and private organizations to enhance awareness about diseases are supporting the growth of the global intestinal pseudo obstruction treatment market. However, high cost of the medical treatment and its possible side-effects are expected to hinder the growth of the global intestinal pseudo obstruction treatment market during the forecast period.

The global intestinal pseudo obstruction treatment market segmentation is based on condition, diagnosis, treatment, end user, regional distribution, and competitive Landscape. Based on region, North America is expected to dominate the global pseudo obstruction treatment market owing to rising awareness about health-related problems and presence of well-developed healthcare in the region.

Major players dominating the global intestinal pseudo obstruction treatment market include Pfizer, Inc., Cipla Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Novartis AG, Johnson & Johnson, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Lupin Limited, among others.

Objective of the Study:

To analyze the historical growth in the market size of global intestinal pseudo obstruction treatment market from 2017 to 2021
To estimate and forecast the market size of global intestinal pseudo obstruction treatment market from 2022E to 2027F and growth rate until 2027F
To classify and forecast global intestinal pseudo obstruction treatment market based on condition, treatment, diagnosis, end user, region, and competitive Landscape
To identify dominant region or segment in the global intestinal pseudo obstruction treatment market
To identify drivers and challenges for global intestinal pseudo obstruction treatment market
To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc, in global intestinal pseudo obstruction treatment market
To identify and analyze the profile of leading players operating in global intestinal pseudo obstruction treatment market
To identify key sustainable strategies adopted by market players in global intestinal pseudo obstruction treatment market

Key Topics Covered:

1. Service Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Intestinal Pseudo Obstruction Treatment Market

5. Voice of Customer
5.1. Factors Contributing to Intestinal Pseudo Obstruction
5.2. Commonly Observed Symptoms of Intestinal Pseudo Obstruction
5.3. Intestinal Pseudo Obstruction Prevalence, By Age Group
5.4. Intestinal Pseudo Obstruction Prevalence, By Gender
5.5. Commonly Used Diagnostic Procedures for Intestinal Pseudo Obstruction
5.6. Preference for Intestinal Pseudo Obstruction Treatment, By Type
5.7. Brand Awareness

6. Global Intestinal Pseudo Obstruction Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Condition (Acute v/s Chronic)
6.2.2. By Diagnosis (Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Others)
6.2.3. By Treatment (Medication, Surgery, Diet, Others)
6.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
6.2.5. By Company (2021)
6.2.6. By Region
6.3. Market Map

7. North America Intestinal Pseudo Obstruction Treatment Market Outlook
7.1. Market Size & Forecast
7.2. Market Share & Forecast
7.3. North America: Country Analysis
7.3.1. United States Intestinal Pseudo Obstruction Treatment Market Outlook
7.3.2. Mexico Intestinal Pseudo Obstruction Treatment Market Outlook
7.3.3. Canada Intestinal Pseudo Obstruction Treatment Market Outlook

8. Europe Intestinal Pseudo Obstruction Treatment Market Outlook
8.1. Market Size & Forecast
8.2. Market Share & Forecast
8.3. Europe: Country Analysis
8.3.1. France Intestinal Pseudo Obstruction Treatment Market Outlook
8.3.2. Germany Intestinal Pseudo Obstruction Treatment Market Outlook
8.3.3. United Kingdom Intestinal Pseudo Obstruction Treatment Market Outlook
8.3.4. Italy Intestinal Pseudo Obstruction Treatment Market Outlook
8.3.5. Spain Intestinal Pseudo Obstruction Treatment Market Outlook

9. Asia-Pacific Intestinal Pseudo Obstruction Treatment Market Outlook
9.1. Market Size & Forecast
9.2. Market Share & Forecast
9.3. Asia-Pacific: Country Analysis
9.3.1. China Intestinal Pseudo Obstruction Treatment Market Outlook
9.3.2. India Intestinal Pseudo Obstruction Treatment Market Outlook
9.3.3. South Korea Intestinal Pseudo Obstruction Treatment Market Outlook
9.3.4. Japan Intestinal Pseudo Obstruction Treatment Market Outlook
9.3.5. Australia Intestinal Pseudo Obstruction Treatment Market Outlook

10. South America Intestinal Pseudo Obstruction Treatment Market Outlook
10.1. Market Size & Forecast
10.2. Market Share & Forecast
10.3. South America: Country Analysis
10.3.1. Brazil Intestinal Pseudo Obstruction Treatment Market Outlook
10.3.2. Argentina Intestinal Pseudo Obstruction Treatment Market Outlook
10.3.3. Colombia Intestinal Pseudo Obstruction Treatment Market Outlook

11. Middle East and Africa Intestinal Pseudo Obstruction Treatment Market Outlook
11.1. Market Size & Forecast
11.2. Market Share & Forecast
11.3. Middle East and Africa: Country Analysis
11.3.1. South Africa Intestinal Pseudo Obstruction Treatment Market Outlook
11.3.2. Saudi Arabia Intestinal Pseudo Obstruction Treatment Market Outlook
11.3.3. UAE Intestinal Pseudo Obstruction Treatment Market Outlook

12. Market Dynamics
12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape
14.1. Pfizer, Inc.
14.2. Cipla Inc.
14.3. GlaxoSmithKline Plc.
14.4. Teva Pharmaceutical Industries Ltd.
14.5. Eli Lilly and Company
14.6. Novartis AG
14.7. Johnson & Johnson
14.8. Dr. Reddy's Laboratories Ltd.
14.9. F. Hoffmann-La Roche AG
14.10. Lupin Limited

15. Strategic Recommendations